Search
Ivacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigational[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage … It was approved by the Food and Drug Administration on January 31, 2012[L768], and by Health Canada in late 2012.
Synonyms: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsMK-3577
go.drugbank.com/drugs/DB14957InvestigationalMK-3577 is under investigation in clinical trial NCT00868790 (A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)).
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigational[L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersChlorothiazide
go.drugbank.com/drugs/DB00880ApprovedInvestigationalVet approvedA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
Mixtures: Supres 150 Tab, Supres 250 TabPBI-1402
go.drugbank.com/drugs/DB05480ExperimentalThe compound activates neutrophils, enhancing their survival and activation with comparable efficacy to GM-CSF, G-CSF and EPO, which are currently used to treat anemia. … Since it stimulates immune activity, it has been considered as a candidate for cancer treatment as well as anemia.
Polyquaternium-10 (400 cps at 2%)
go.drugbank.com/drugs/DB11356ApprovedPolyquaternium-10 is a quaternized hydroxyethyl cellulose and a polycationic polymer. It is commonly found in cosmetics and personal care products to mainly reduce static electricity and form films.
Synonyms: Polyquaternium-10 (400 cps at 2%)MK-0777
go.drugbank.com/drugs/DB12238InvestigationalMK-0777 has been used in trials studying the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEmapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigationalEmapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. … [L4840] As well, emapalumab was given the status of PRIME by the EMA.[L4845]
Pyrethrum extract
go.drugbank.com/drugs/DB11087ApprovedPyrethrum-containing mixtures are used as a common insecticide to control specific pest species. Pyrethrum extract is also used used to treat head, body, and pubic lice infections.
Mixtures: KWELL-P %0,3 + %3 MEDİKAL ŞAMPUAN, 120 ML, KWELL-P %0,3 + %3 MEDİKAL ŞAMPUAN, 60 MLAbiprubart
go.drugbank.com/drugs/DB19333InvestigationalAbiprubart is being evaluated for its efficacy and safety in participants with Sjögren's Disease in clinical trial NCT06531395
Synonyms: Gamma4 heavy chain humanized (1-441) [VH (Homo sapiens IGHV1-3*01 (83.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.7] (26-33.51-58.97-103)) (1-114)-Homo sapiens IGHG4*01, nG4m(a) CH2 L92, G4v5 h P10 (CH1, Immunoglobulin G4-kappa, anti-[Homo sapiens CD40 (TNFRSF5, tumor necrosis factor receptor (TNFR) superfamily member 5, p50)], humanized monoclonal antibody